Skip to content
value.today

CoRegen, Inc.

🇺🇸 Aspen, Colorado, USABiotechnologyFounded 2022
Total raised
$121 M
5 rounds on record
Latest round
$14 M
Oct 2025
First round on record
Feb 2024
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of CoRegen, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$14 MNo. 5$10 to $50 million

CoRegen, Inc.: Raise no. 5, Oct 2025

Investors in this round

1 investor had bought by the notice of Feb 26, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$540,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter W. Gelinas · Executive Officer
  • Sonal Gupta · Executive Officer
  • Sonja Nelson · Executive Officer · Chief Financial Officer and Secretary
  • Steve Gorlin · Executive Officer, Director · President and Vice Chairman of the Board
  • Bert W. O'Malley · Director
  • Edward J. Benz, Jr. · Director
  • Jonathan W. Simons · Director
  • Lee J. Fleisher · Director
  • Suneet J. Varma · Director
  • William J. Haseltine, PhD. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Stonehaven, LLC (CRD 118913) · broker-dealer Terrance Joseph Philips (CRD 8015702) · New York, New YorkSold in OH
  • Stonehaven, LLC (CRD 118913) · broker-dealer Marc Christopher Rucinski (CRD 4543011) · New York, New YorkSold in OH

Signed by Sonja Nelson, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 26, 2026. Read the notice at the SEC.

equitySEC
Apr 2025$63 MNo. 4$50 to $250 million

CoRegen, Inc.: Raise no. 4, Apr 2025

Investors in this round

8 investors had bought by the notice of May 22, 2025: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$63 M of $63 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,130,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Clifford C. Dasco, M.D. · Executive Officer, Director · Chief Medical Officer of the Issuer
  • David Lonard, PhD · Executive Officer · Chief Science Officer of the Issuer
  • John Thomas, Jr. · Executive Officer · Chief Financial Officer and Secretary of Issuer
  • Steve Gorlin · Executive Officer, Director · President of the Issuer
  • Bert W. O'Malley · Director
  • Edward J. Benz, Jr. · Director
  • Jonathan W. Simons · Director
  • Lee J. Fleisher, M.D. · Director
  • Suneet J. Varma · Director
  • William J. Haseltine, PhD. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • M M Dillon & Co. LLC (CRD 19878) · broker-dealer Elena Ulansky (CRD 7654267) · Greenwich, ConnecticutSold in FL, NY, TX
  • M M Dillion & Co. LLC (CRD 19878) · broker-dealer Jeff Robert Swarz (CRD 1563420) · Greenwich, ConnecticutSold in FL, NY, TX

Remarks in the notice

  • On fees: “Includes 7% warrant coverage issued to Broker where applicable sales commissions were payable”

Signed by John C. Thomas Jr., Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed May 22, 2025. Read the notice at the SEC.

equitySEC
Feb 2025$10 MNo. 3$10 to $50 million

CoRegen, Inc.: Raise no. 3, Feb 2025

Investors in this round

1 investor had bought by the notice of Feb 28, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Clifford C. Dasco, M.D. · Executive Officer, Director · Chief Medical Officer of the Issuer
  • David C. Lonard, PhD · Executive Officer · Chief Science Officer of the Issuer
  • John C. Thomas, Jr. · Executive Officer · Chief Financial Officer and Secretary of the Issuer
  • Shawn C. Tomasello · Executive Officer, Director · Chief Executive Officer of the Issuer
  • Bert W. O'Malley · Director
  • Edward J. Benz, Jr. · Director
  • Jonathan W. Simons · Director
  • Lee C. Fleisher, M.D. · Director
  • Steve C. Gorlin · Director
  • William C. Haseltine, PhD. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • M M Dillion & Co. LLC (CRD 19878) · broker-dealer Jeff Robert Swarz (CRD 1563420) · Greenwich, ConnecticutSold in NY
  • M M Dillon & Co. LLC (CRD 19878) · broker-dealer Elena Ulansky (CRD 7654267) · Greenwich, ConnecticutSold in FL

Remarks in the notice

  • On fees: “Includes 7% warrant coverage issued to Broker where applicable sales commissions were payable”

Signed by John C. Thomas Jr., Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed Feb 28, 2025. Read the notice at the SEC.

equitySEC
Jan 2025$21 MNo. 2$10 to $50 million

CoRegen, Inc.: Raise no. 2, Jan 2025

Investors in this round

7 investors had bought by the notice of Feb 28, 2025: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,400,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Clifford C. Dasco, M.D. · Executive Officer, Director · Chief Medical Officer of the Issuer
  • David C. Lonard, PhD · Executive Officer · Chief Science Officer of the Issuer
  • John C. Thomas, Jr. · Executive Officer · Chief Financial Officer and Secretary of the Issuer
  • Shawn C. Tomasello · Executive Officer, Director · Chief Executive Officer of the Issuer
  • Bert W. O'Malley · Director
  • Edward J. Benz, Jr. · Director
  • Jonathan W. Simons · Director
  • Lee C. Fleisher, M.D. · Director
  • Steve C. Gorlin · Director
  • William C. Haseltine, PhD. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • M M Dillion & Co. LLC (CRD 19878) · broker-dealer Jeff Robert Swarz (CRD 1563420) · Greenwich, ConnecticutSold in NY
  • M M Dillon & Co. LLC (CRD 19878) · broker-dealer Elena Ulansky (CRD 7654267) · Greenwich, ConnecticutSold in FL

Remarks in the notice

  • On fees: “Includes 7% warrant coverage issued to Broker where applicable sales commissions were payable”

Signed by John C. Thomas Jr., Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed Feb 28, 2025. Read the notice at the SEC.

equitySEC
Feb 2024$15 MNo. 1$10 to $50 million

CoRegen, Inc.: Raise no. 1, Feb 2024

Investors in this round

1 investor had bought by the notice of Feb 22, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M (amount offered: indefinite)
Smallest investment taken
$14,500,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David C. Lonard, PhD · Executive Officer · Chief Science Officer of the Issuer
  • John C. Thomas, Jr. · Executive Officer · Chief Financial Officer of the Issuer
  • Steve C. Gorlin · Executive Officer, Director · Chief Executive Officer of the Issuer
  • Bert W. O'Malley, M.D. · Director
  • Clifford C. Dasco, M.D. · Director
  • David M. Cornell, II · Director
  • Edward J. Benz, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John C. Thomas, Jr., Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 22, 2024. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CoRegen, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2026).

    SEC Form D · Feb 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2026

That is all the official record says: CoRegen, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of CoRegen, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CoRegen, Inc.
NameRoleNamed in
Peter W. GelinasExecutive officerFeb 2026
Sonal GuptaExecutive officerFeb 2026
Sonja NelsonChief Financial Officer and SecretaryFeb 2026
Steve GorlinPresident and Vice Chairman of the BoardFeb 2026
Clifford C. Dasco, M.D.Chief Medical Officer of the IssuerMay 2025
David Lonard, PhDChief Science Officer of the IssuerMay 2025
John Thomas, Jr.Chief Financial Officer and Secretary of IssuerMay 2025
David C. Lonard, PhDChief Science Officer of the IssuerFeb 2025
John C. Thomas, Jr.Chief Financial Officer and Secretary of the IssuerFeb 2025
Shawn C. TomaselloChief Executive Officer of the IssuerFeb 2025
Steve C. GorlinChief Executive Officer of the IssuerFeb 2024
Bert W. O'MalleyDirectorFeb 2026
Edward J. Benz, Jr.DirectorFeb 2026
Jonathan W. SimonsDirectorFeb 2026
Lee J. FleisherDirectorFeb 2026
Steve GorlinPresident and Vice Chairman of the BoardFeb 2026
Suneet J. VarmaDirectorFeb 2026
William J. Haseltine, PhD.DirectorFeb 2026
Clifford C. Dasco, M.D.Chief Medical Officer of the IssuerMay 2025
Lee J. Fleisher, M.D.DirectorMay 2025
Lee C. Fleisher, M.D.DirectorFeb 2025
Shawn C. TomaselloChief Executive Officer of the IssuerFeb 2025
Steve C. GorlinDirectorFeb 2025
William C. Haseltine, PhD.DirectorFeb 2025
Bert W. O'Malley, M.D.DirectorFeb 2024
David M. Cornell, IIDirectorFeb 2024